United States / English

EMD Millipore is now MilliporeSigma

EB Programs: Our Grant Programs

Unlock your molecule's potential.

We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why we have developed our EB Grant programs that we run on regular basis in different regions of the world. These programs allow grant recipients receive free products and services.

2019 Taiwan

Apply to our Advance Biotech Grant Program Today!

We are hosting our 8th edition, open for Taiwan biotech companies, to help you accelerate to clinic faster.

Apply now for a chance to win free process solution products and services; and/or process development support.

Registration and rules

2019 China

Apply to our Advance Biotech Grant Program Today!

We are hosting our 7th edition, open for China biotech companies, to help you accelerate to clinic faster.

Apply now for a chance to win free process solution products and services; and/or process development support.

Registration and rules

2018 - 2019 USA and Canada

Our 2019 Advance Biotech Grant Program for North America

We have hosted our 2019 Advance Biotech Grant Program for North American biotech companies, to help you accelerate to clinic faster.

The three grant recipients are:

  • RAFT Pharmaceuticals (San Diego, California), for its approach to treat chronic pain using a biologic to selectively inhibit neuroinflammation without affecting normal motor or sensory function.

  • Rubicon Biotechnology (Anaheim, California), for developing a therapeutic protein, Fv-Hsp72, designed to protect and salvage cells damaged from an acute event, such as traumatic brain injury.

  • TechnoVax Inc (Elmsford, New York), for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.
In support of the growing biotech ecosystem, grant recipients receive between $40,000 and $100,000 in MilliporeSigma products and process development support.

Read the Grant winner announcement

2018 - Europe

Our 2018 Advance Biotech Grant Program for Europe

We have hosted our 2018 Advance Biotech Grant Program, the 5th edition, for European* biotech companies, to help you accelerate to clinic faster.


  • GenoScience Pharma (France), to explore new agents such as GNS561 — a never-before-used mechanism-of-action in commercialized cancer treatments / anti-cancer drugs in the pipeline.

  • GlioCure (France), for developing an anti-tumor and neuroprotective peptide, GC01, to treat the most frequent and aggressive type of brain tumor, glioblastoma.

  • ResoTher Pharma (Denmark), to develop new medicines for cardiovascular and inflammatory disorders.
Each grant recipient has received between €50,000 and €100,000 in MilliporeSigma products and services to help solve their challenges.

Read the Grant winner announcement

[*Netherlands, Belgium, Switzerland, United Kingdom, Ireland, France, Germany, Denmark, Finland, Norway, Austria, Spain, Sweden]

2016 - Europe


  • GeneQuine Biotherapeutics (first prize), for developing novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need
  • TILT Biotherapeutics (second prize), for enabling tumor T-cell therapy with oncolytic viruses.
  • Reneuron (third prize), for developing novel stem cell therapies targeting areas of significant unmet or poorly met medical need
  • Magnus Life Science (fourth prize), for funding, building and managing companies to translate innovative, curiosity driven science into therapeutics and devices that bring significant benefits to patients

Recipients received between €25,000 and €100,000 in technologies and services to accelerate therapeutics to market. View Press Release.

2015 - Asia


  • Beijing Biokey, for developing a monoclonal antibody for the treatment of fibriotic disease
  • Guangdong Jia Genetic Medicine Engineering Research Center, for developing novel therapies to treat cancer and autoimmune diseases
  • Hangzhou DAC Biotech, for developing antibody drug conjugates to treat cancer
  • Akeso Biopharma, for developing a pipeline of antibodies targeting cancer, cariovascular and immune diseases
  • Shanghai Mattel Biotechnology, for developing an innovative long acting fusion FVIII to treat hemophilia

Each grant recipient received 280,000 CNY in technologies and services.

2014 - USA


  • NGM Biopharmaceuticals, for developing biologics for the treatment of cardiometabolic conditions, bile acid-related disease, and potentially other diseases resulting from manifestations of cardiometabolic abnormalities and metabolic related cancers

NGM was awarded $89K in products and services. View Announcement.

Best practices for biotechnology companies from industry experts. Click on a topic to learn more.

If you want to be contacted regarding our next Emerging Biotech Grant Program, please leave your details and we will contact you.

Biotech Resource Hub: Stay Current

Advance Biotech Grant Program – Accelerating Therapeutic Development in Life Science

The Life Science business of MilliporeSigma is expanding its commitment to the global biotech community with its Advance Biotech Grant Program. Through the newly expanded grant program, every six months, three recipients around the globe will be awarded a total of €200,000 in free services and products to address their process development challenges. In total, six companies will benefit from the Advance Biotech Grant Program each year. Press Release

Find out more about our programs:

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

More details about EB Programs>

WEBINAR: Accelerated ADC Development with Integrated Supply Chain Solutions

Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.

Watch Now >

WEBINAR: RNA Based Therapeutics and Vaccines: Bioprocessing Technology Trends

Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.

Watch this Webinar >

WEBINAR: Managing Process Scale-up and Tech Transfer

Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.

Watch this Webinar >

Webinars On-Demand >

WHITE PAPER: 2017 Life Science Executive Summit

Establishing an open dialog within the biotech community....

Read more and download >

The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.

Read the study >

Contact Us

Research. Development. Production.

We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.

© 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
EMD Millipore is a part of Merck KGaA, Darmstadt, Germany.